S103 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL

Autor:	Danielle Canioni, C. thieblemont, Marion Alcantara, O. Hermine, Marie-Pierre Moles, M. H. Delfau-Larue, C. Bodet-Milin, Vincent Delwail, G. Damaj, Victoria Cacheux, V. Ribrag, Asma Beldi-Ferchiou, N. Daguindau, G. Salles, E. Macintyre, Steven Legouill, Arnaud Jaccard, T. Gastinne
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty chemistry.chemical_compound Autologous stem-cell transplantation MRD Response chemistry Obinutuzumab business.industry DHAP Internal medicine medicine Hematology business
Zdroj:	HemaSphere. 3:3
ISSN:	2572-9241
DOI:	10.1097/01.hs9.0000558632.47592.16
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d6b7d402454398908ac709b30bdd048d https://doi.org/10.1097/01.hs9.0000558632.47592.16 Zobrazit plný text záznamu Plný text